All In Biotech

Drug Trial Radar · NCT05786573

A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety and Dose Confirmation Run-In Period, To Evaluate the Efficacy and Safety of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

134

Planned (sponsor's estimate)

Start

Sep 25, 2023

Primary completion

Jun 30, 2026

Study completion Aug 31, 2026

Sponsor

Lead sponsor
Zenas BioPharma (USA), LLCIndustry
Sponsor type
Industry
First posted
Mar 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Conditions

  • Warm Autoimmune Hemolytic Anemia

Interventions

  • ObexelimabDrug

    Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.

  • ObexelimabDrug

    Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Dose Confirmation Run-in Period (SRP)Time frame: 24 weeks
  2. Randomized Control Period (RCP)Time frame: 24 weeks

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii

    Gdansk, Pomeranian Voivodeship, Poland

  • Hospital Universitario de Burgos

    Burgos, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • Plymouth Hospitals NHS Trust

    Plymouth, Devon, United Kingdom

  • Kent and Canterbury Hospital

    Canterbury, Kent, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.